Sorafenib-d3 (tosylate)
Sorafenib-d3 (Donafenib-d3) tosylate is the deuterium labeled Sorafenib. Sorafenib is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib-d3tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib-d3tosylate induces autophagy and apoptosis. Sorafenib-d3tosylate has anti-tumor activity. Sorafenib is a ferroptosis activator[1].
Product Specifications
CAS Number
1333386-17-6
Product Name Alternative
Donafenib (tosylate) ; Bay 43-9006-d3 (tosylate)
UNSPSC
12352005
Target
Apoptosis; Autophagy; Ferroptosis; FLT3; Isotope-Labeled Compounds; Raf; VEGFR
Related Pathways
Apoptosis; Autophagy; MAPK/ERK Pathway; Others; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=S(O)(C1=CC=C(C=C1)C)=O.[2H]C([2H])([2H])NC(C2=CC(OC3=CC=C(C=C3)NC(NC4=CC(C(F)(F)F)=C(C=C4)Cl)=O)=CC=N2)=O
Molecular Formula
C28H21D3ClF3N4O6S
Molecular Weight
640.05
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
Phase 4
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
